Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

Im Ringen um den stark umkämpften Markt für Adipositas-Medikamente hat der US-Pharmakonzern Pfizer einen Rückschlag erlitten ...

Pfizer Inc. dejará de desarrollar una píldora contra la obesidad que ha sido seguida de cerca por los inversores, un duro ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...